GVR Report cover Mycoplasma Testing Market Size, Share & Trends Report

Mycoplasma Testing Market Size, Share & Trends Analysis By Product (Instruments, Kit & Reagents, Services), By Technology (PCR, ELISA, Direct Assay, Microbial Culture), By Application, By End Use, And Segment Forecasts, 2020 - 2027

  • Report ID: GVR-1-68038-897-8
  • Number of Pages: 120
  • Format: Electronic (PDF)
  • Historical Range: 2016 - 2018
  • Industry: Healthcare

Report Overview

The global mycoplasma testing market size was valued at USD 627.16 million in 2019 and is expected to witness attractive growth over the forecast period. Increasing investments in R&D activities have contributed to huge revenue for the market. The rising introduction of novel technologies by key players is expected to further boost growth. The rise in cell culture contamination is also another factor driving growth.

U.S. mycoplasma testing market size

Due to the limitation of culture methods, researchers are involved in the identification and development of more rapid and accurate mycoplasma tests in recent years. The primary advantages of such rapid tests would be high sensitivity, the capability of identifying a wide range of mycoplasma species, and cycle time reduction, thus, reducing the production time. These rapid methods would also facilitate faster decision making to minimize the spread of contamination. One such example of an alternative method for culture-based testing is Nucleic Acid-based Technology (NAT) which allows rapid detection of mycoplasma in cell culture. In 2018, American Type Culture Collection announced the launch of its new Polymerase Chain Reaction (PCR) based service that helps detect contaminants in mycoplasma cell cultures.

Increasing research activities conducted by pharmaceutical and biotechnology companies are resulting in the adoption of new technologies for drug discovery and development. In 2018, Boehringer Ingelheim announced its plans to invest around USD 259 million for its new Biologicals Development Center (BDC), to be located at its R&D site in Germany. Merck is also planning to invest USD 16 billion in R&D over the next five years, in addition to its annual investment of USD 7 billion. Thus, a huge amount of spending in R&D activities is expected to drive developments in this field, thereby boosting the demand for mycoplasma testing products.

Research activities in the pharmaceutical and biotechnology sectors are increasingly supported by various government authorities. For instance, the U.S. government is providing financial support to the global pharmaceutical companies in order to facilitate research-based activities for new drug development. In April 2019, the U.S. Food and Drug Administration (FDA) announced its plan to amend the regulations pertaining to the only testing method used for the detection of mycoplasma. According to the agency, the regulation is restrictive in nature and thus, prevents the use of other testing methods which may have the potential to accurately detect mycoplasma. Such changes in biologics regulation are expected to improve sensitivity and specificity in mycoplasma detection tests, evolving new technologies. Thus, an increase in government funding for pharmaceutical and biotechnology research has stimulated R&D activities, thereby, fostering the huge application of mycoplasma testing products.

More than 190 mycoplasma species are known, out of which only eight are responsible for more than 95% of cell culture contaminations. Poor cultural practices, dust, aerosols, and cross-contamination due to faulty or broken laminar flow are some of the factors due to which there is an increase in the number of cell culture contamination events. Additionally, mycoplasma contamination adversely affects the research work of scientists in laboratories. Human mycoplasma is a key source of cell culture contamination that occurs due to laboratory technicians who are infected with M. orale or M. fermentans. Hence, testing of such bacteria is considered as a significant requirement to generate robust data in the field of biomedical research.

Product Insights

On the basis of products, the mycoplasma testing market is segmented into instruments, kits and reagents, and services. Kits and reagents accounted for the largest market share in 2019 owing to the repeated purchase of consumables for the detection of mycoplasma in cell culture research work and other applications. Kit and reagents segment is further divided into PCR assays, nucleic acid detection kits, stains, elimination kits, and standards and controls.

PCR assays aid in accurate mycoplasma identification and provides results within a few hours. Detection of mycoplasma can be done easily by verifying bands of DNA fragments using electrophoresis, which is mostly used by PCR assays that do not need preparation of labeled probes. For instance, Takara Bio Inc. developed a PCR mycoplasma detection set that does not allow further amplification of DNA originating from other sources, such as cultured cells that majorly affect detection results.

Instruments are expected to showcase significant growth over the forecast period, due to the growing availability of automated instruments for the detection of mycoplasma. PCR systems offer a better approach that enables rapid detection and provides results in a short amount of time. For instance, Bio-Rad developed a PCR-based CFX96 Touch Real-Time PCR Detection System. It is a flexible and precise PCR detection, with six channels that combine advanced and effective optical technology, with precise control in temperature. This helps deliver a reliable and sensitive detection method for both multiplex and singleplex reactions.

Technology Insights

On the basis of technology, the PCR segment held the largest market share in 2019. This technology enables the detection of multiple species of mycoplasma while separating other contaminating DNA. It provides test results with high specificity and efficiency. Ease of procedure and rapid detection are some of the major advantages offered by this technique. For instance, LookOut Mycoplasma PCR Detection Kit developed by Merck KGaA facilitates the detection of Ureaplasma, Mycoplasma, and Acholeplasma contamination in cell-derived biologicals and cell culture lines.

Direct assays are expected to showcase lucrative growth over the forecast period. The high level of certainty provided by these tests has been one of the key reasons for its significant market growth. However, some disadvantages associated with direct assays include low sensitivity and the requirement for a prolonged incubation period prior to detection. Microbial culture techniques are also highly demanded due to increasing applications in mycoplasma contamination testing and the rising number of research activities conducted in the field of the biopharmaceutical industry.

Application Insights

Cell line testing held the largest market share in terms of revenue in 2019 owing to the growing number of research activities undertaken in the field of cell culture. It is also expected to witness the highest growth over the forecast period due to the rise in mycoplasma contamination in cell culture. Mycoplasma contamination can lead to alterations in cell culture metabolite formations and develop toxins. This gives cell line testing and authentication prime importance in the pharmaceutical and biopharmaceutical industries.

The end of the production cell testing segment is anticipated to exhibit significant growth over the forecast period owing to the huge amount of cell harvest and a growing number of clinical trials for drug discovery and development. This application segment includes genetic analysis of the transgenes using techniques, such as Southern Blotting, transgene copy number, and mRNA sequencing. Thus, quality control measures taking place in the process of drug discovery are majorly triggering the growth of this segment.

End-use Insights

Pharmaceutical and biotechnology companies held the largest market share in 2019 due to huge investments in R&D activities by these companies, which has led to progressive research related to drug discovery. These companies are engaged in quality checks of raw materials, thus, ensuring biological safety management. Moreover, the biopharmaceutical industry is also growing due to an increase in the incidence of diseases such as rheumatoid arthritis and psoriasis.

Global mycoplasma testing market share

Contract Research Organizations (CROs) is expected to showcase lucrative growth over the forecast period owing to rising research services made available by these organizations. They require the use of mycoplasma tests needed to maintain the sterility of cultures in preclinical research and biopharmaceutical development, thus, ensuring the quality of the outsourced testing services.

Regional Insights

In 2019, North America dominated the market for mycoplasma testing owing to rising healthcare spending and investments by the U.S. government to promote research-based activities in biopharmaceutical industries. The production of biopharmaceuticals in North America is also growing, which requires highly purified cultures to produce therapeutics. As per the National Science Foundation, in 2019, the R&D sector in the U.S. showed a prominent growth, which is expected to positively influence regional growth.

The Asia Pacific is projected to display lucrative growth over the forecast period. This is due to the significant awareness and funding initiatives generated by countries such as India. The Indian government is undertaking various strategic initiatives to facilitate additional R&D activities for the introduction of new drugs. Moreover, regulatory policies enforced by healthcare organizations favoring improvements in biosafety quality are expected to increase growth opportunities in the near future. For instance, China has a number of regulatory bodies, such as the Ministry of Health, overseeing laboratory and experiment approval, and biosafety oversight.

Mycoplasma Testing Market Share Insights

Key market players include Bionique Testing Laboratories, Inc.; Lonza Group Ltd.; Merck KGaA; PromoCell GmbH; ATCC (American Type Culture Collection); Biological Industries Israel Beit Haemek Ltd.; Charles River Laboratories International, Inc.; Thermo Fisher Scientific; and InvivoGen.

The major strategies adopted by these companies include mergers and acquisitions, new product development, and geographical expansions. For instance, in 2019, Lonza expanded its mycoplasma detection portfolio by launching the new luminometer Lucetta 2-a product used to accelerate and simplify the detection of mycoplasma in cell cultures. Additionally, in March 2018, Charles River Laboratories International, Inc. announced key expansions to its biologics testing solutions infrastructure to support the development, characterization, and release of biosimilar and biologics.

Mycoplasma Testing Market Report Scope

Report Attribute


Market size value in 2020

USD 708.2 million

Revenue forecast in 2027

USD 1.87 billion

Growth Rate

CAGR of 14.9% from 2020 to 2027

Base year for estimation


Historical data

2016 - 2018

Forecast period

2020 - 2027

Quantitative units

Revenue in USD Million and CAGR from 2020 to 2027

Report coverage

Revenue forecast; company share; competitive landscape; growth factors and trends

Segments covered

Product, technology, application, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; Spain; France; Italy; Russia; Japan; India; China; South Korea; Singapore; Australia; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE

Key companies profiled

Bionique Testing Laboratories, Inc.; Lonza Group Ltd.; Merck KGaA; PromoCell GmbH; ATCC (American Type Culture Collection); Biological Industries Israel Beit Haemek Ltd.; Charles River Laboratories International, Inc.; Thermo Fisher Scientific; InvivoGen.

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global mycoplasma testing market report on the basis of product, technology, application, end-use, and region:

  • Mycoplasma Testing Product Outlook (Revenue, USD Million, 2016 - 2027)

    • Instruments

    • Kits & Reagents

      • PCR Assays

      • Nucleic Acid Detection Kits

      • Stains

      • Elimination Kits

      • Standards & Controls

      • Others

    • Services

  • Mycoplasma Testing Technology Outlook (Revenue, USD Million, 2016 - 2027)

    • PCR

    • ELISA

    • Direct Assay

    • Indirect Assay

    • Microbial Culture Techniques

    • Enzymatic Methods

  • Mycoplasma Testing Application Outlook (Revenue, USD Million, 2016 - 2027)

    • Cell Line Testing

    • Virus Testing

    • End of Production Cells Testing

    • Others

  • Mycoplasma Testing End-use Outlook (Revenue, USD Million, 2016 - 2027)

    • Academic Research Institutes

    • Cell Banks

    • Contract Research Organizations

    • Pharmaceutical & Biotechnology Companies

    • Others

  • Mycoplasma Testing Regional Outlook (Revenue, USD Million, 2016 - 2027)

    • North America

      • The U.S.

      • Canada

    • Europe

      • Germany

      • The U.K.

      • Spain

      • France

      • Italy

      • Russia

    • Asia Pacific

      • Japan

      • China

      • India

      • South Korea

      • Singapore

      • Australia

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • MEA

      • South Africa

      • Saudi Arabia

      • UAE

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.